ArticleJournal of neuro-oncology2020

Evidence for improved survival with bevacizumab treatment in recurrent high-grade gliomas: a retrospective study with ("pseudo-randomized") treatment allocation by the health insurance provider.

Susanne Hofmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.